drugset / Trial / NCT00675948

Study to Compare the Safety and Tolerability of Sativex® in Patients With Cancer Related Pain

NCT00675948

Phase 3 Completed 43 enrolled Jazz Pharmaceuticals
Non-randomizedSingle-groupOpen-labelSupportive care

Summary

The purpose of this study is to assess the safety and tolerability of long term therapy with Sativex® and GW-2000-02.

Timeline

Start
2002-04
Primary completion
2006-09
Completion
2006-09

Drugs

EvaluationDrugModalityDoseRoute
Subject GW-2000-02 Unknown 130 mg Other
Subject Nabiximols Other / unclassified 120 mg Other
Subject Nabiximols Other / unclassified 130 mg Other

Indications